PLCG2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4199434	0.79	3/20
SCHEMBL5446081	0.79	3/20
SCHEMBL2304168	1.00	2/20
SCHEMBL1653100	0.69	2/20
SCHEMBL6215530	0.67	2/20
SCHEMBL6794629	0.66	2/20
SCHEMBL6794631	0.66	2/20
SCHEMBL749657	0.65	2/20
SCHEMBL1082266	0.65	2/20
SCHEMBL6793830	0.62	2/20
SCHEMBL6793839	0.62	2/20
SCHEMBL4565034	0.62	2/20
SCHEMBL1277212	0.62	2/20
SCHEMBL5268675	0.62	2/20
SCHEMBL2659473	0.60	2/20
SCHEMBL2977330	0.60	2/20
SCHEMBL1653052	0.60	2/20
SCHEMBL1277489	0.59	2/20
SCHEMBL6801416	0.58	2/20
SCHEMBL6801419	0.58	2/20

Clinical trials — most relevant to PLCG2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	PHASE2	RECRUITING
Study to Investigate the Effect of PBF-680 on Forced Expiratory Volume in 1 Second (FEV1) in Asthmatic Patients	PHASE2	COMPLETED
Anti-CD38 Antibody Treating APS With Thrombocytopenia	PHASE2	RECRUITING
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib	PHASE1	ACTIVE_NOT_RECRUITING
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability	PHASE1	COMPLETED
Molecular Markers of Human Sperm Function	nan	WITHDRAWN
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
The Study Aims to Investigate the Effects of Oral Inositols on Insulin-resistance in Children With Obesity.	nan	UNKNOWN
Partial PTEN Deletion in Breast Cancer	nan	UNKNOWN
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Clinical Characteristics of Primary Liver Cancer	nan	UNKNOWN
Liver Cancer Prognosis Investigation Study	nan	NOT_YET_RECRUITING
Free Fatty Acid Induced Insulin Resistance	nan	COMPLETED
Candida Associated Cytokines in Oral Leukoplakia	nan	COMPLETED
Plaque Calcium Characterization and Ruptured Plaques	nan	UNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer	nan	COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)	nan	COMPLETED
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis	nan	COMPLETED
Comparison of Two Types of Calcium (Ca²⁺) Ionophore Treatments for Oocyte Activation in Cases of Suboptimal Fertilization Potential	nan	NOT_YET_RECRUITING
Exome Sequencing for Atypical Femoral Fractures	nan	COMPLETED
Calciotropic Effects After HCG Stimulation Test	nan	COMPLETED
The Dragon PLC Trial (DRAGON-PLC)	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a PLCG2 binder may also engage these)

Protein	Name	Similarity
Q8CIH5	—	1.000	Q8CIH5 →
P24135	—	1.000	P24135 →
P10686	—	1.000	P10686 →
PLCG1	1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1	1.000	landscape →
Q62077	—	1.000	Q62077 →
Q22070	—	0.999	Q22070 →
P08487	—	0.998	P08487 →
B4NBB0	—	0.993	B4NBB0 →
Q9H1H9	—	0.992	Q9H1H9 →
Q03603	—	0.992	Q03603 →
Q9NPF8	—	0.991	Q9NPF8 →
B3M383	—	0.990	B3M383 →
Q9TTH8	—	0.990	Q9TTH8 →
B0XDC4	—	0.989	B0XDC4 →
F4IDQ6	—	0.989	F4IDQ6 →
O12990	—	0.989	O12990 →
P52332	—	0.989	P52332 →
Q9JK15	—	0.989	Q9JK15 →
KDM5B	Lysine-specific demethylase 5B	0.989	landscape →
Q5XI69	—	0.989	Q5XI69 →
B4LX81	—	0.989	B4LX81 →
DGKA	Diacylglycerol kinase alpha	0.989	landscape →
A2CEA7	—	0.988	A2CEA7 →
A1ZAJ2	—	0.988	A1ZAJ2 →
KAT8	Histone acetyltransferase KAT8	0.988	landscape →
Q11208	—	0.988	Q11208 →
Q54RB7	—	0.988	Q54RB7 →
P20192	—	0.988	P20192 →
Q5XI06	—	0.988	Q5XI06 →
O95759	—	0.988	O95759 →